Redeye: Alligator Bioscience (Q3 Review) - Rights Issue of up to SEK120m
RefinitivЗаймёт меньше минуты
Redeye reviews Alligator Bioscience’s Q3 report 2025. The main event is the rights issue of SEK120m announced on Wednesday evening. The main positive event was the extensive investigator-sponsored study in bile duct cancer in France.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/
Чтобы прочитать эту статью, зарегистрируйтесь на TradingView — это бесплатно